Psoriasis News

Roflumilast foam 0.3% improved patient-reported outcomes in scalp and body psoriasis, according to a poster presentation at the Fall Clinical Dermatology Conference.

Earlier this year, the National Psoriasis Foundation published an extensive report on the health impacts of psoriasis, including data on social stigma associated with the disease, health disparities and comorbidities.

WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.

Patients with cancer who received immune checkpoint inhibitors exhibited increased risk for psoriasis compared with those treated with chemotherapy or targeted therapy.

WASHINGTON — Dactylitis, psoriasis and other non-musculoskeletal manifestations of psoriatic arthritis can be accurately monitored through patient self-reporting, according to data presented at ACR Convergence 2024.

The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.

Around the world, approximately 125 million people suffer from psoriasis and psoriatic arthritis. On Oct. 29, World Psoriasis Day, we recognize the challenges of and treatment advances for patients with psoriasis.

A study found patients with psoriasis in sensitive or difficult-to-treat areas experienced success with Tremfya, according to a press release.

Patients with rheumatoid arthritis or psoriatic arthritis starting biologic disease-modifying antirheumatic drugs have a higher risk for interstitial lung disease vs. the general population, with the highest risk found in RA, data show.